Herpetic Keratitis Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Topical Steroids, Anti-viral Drugs, Interferons, and Others), By Disease Type (Epithelial, Disciform, Neurotrophic, Necrotizing), By Route of Administration (Oral and Topical) By End Users (Hospitals, Specialty Clinics, Homecare, Others) and Region Forecast 2020-2031

Herpetic Keratitis Market size was valued at US$ 837.3 million in 2024 and is expected to reach US$ 1,259.0 million by 2031, growing at a significant CAGR of 6% from 2025-2031. Herpetic keratitis is a form of keratitis caused by recurrent herpes simplex virus infection in the cornea, which begins with infection of the epithelial cells on the surface of the eye and retrograde infection of nerves serving the cornea and is characterized by swelling of the conjunctiva and eyelids. Based on the treatment type, the anti-viral segment is anticipated to dominate the market share over the forecast period.

According to the World Health Organization, nearly 3.7 billion people under the age of 50 years have herpes simplex virus type 1 infection, and around 491 million people aged 15 to 49 years have herpes simplex virus type 2 infection. The increasing prevalence of chronic diseases, rapid advancements in the healthcare sector, and high adoption of techniques are the major market growth drivers, while the high cost of treatment could hinder the growth of the market. The increasing rate of mergers and acquisitions will act as an opportunity for geographical expansion of the market.

key Developments

• In April 2019, Fera Pharmaceuticals’s Avaclyr was approved by the US FDA for the treatment of acute herpetic keratitis in patients.
• In Sep 2021, Aurobindo Pharma received an Indian patent for Valacyclovir, an anti-viral drug from the Indian patent office.